Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine. - Kopruszinski CM; Linley JE; Thornton P; Walker AS; Newton P; Podichetty S; Ruparel RH; Moreira de Souza LH; Navratilova E; Meno-Tetang G; Gurrell I; Dodick DW; et al. (Brain : a journal of neurology, 2025)